222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191
Showing 1 to 10 of 19 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2100048518 | 2021-10-31 | 2021-07-09 | A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequential regimen and low-dose multi-target regimen in the treatment of idiopathic membranous nephropathy A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequent ... | A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequential regimen and low-dose multi-target regimen in the treatment of idiopathic membranous nephropathy A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequent ... | idiopathic membranous nephropathy | low-dose multi-target group:No;tacrolimus combined with belimumab sequential group:No;intravenous cyclophosphamide pulse group:No; low-dose multi-target group:No;tacrolimuscombined with belimumabsequential group:No;intravenous cycl ... | The Second Affiliated Hospital of Xi'an Jiaotong University | NULL | Pending | 18 | 70 | Both | low-dose multi-target group:100;tacrolimus combined with belimumab sequential group:100;intravenous cyclophosphamide pulse group:100; | China | |
2 | NCT04745728 (ClinicalTrials.gov) | April 14, 2021 | 4/2/2021 | Different Immunosuppressive Treatment in iMN | Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort | Idiopathic Membranous Nephropathy | Drug: Prednisone;Drug: Cyclophosphamide;Drug: Rituximab | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 80 Years | All | 200 | Phase 3 | China |
3 | ChiCTR2000033766 | 2020-07-01 | 2020-06-11 | Diagnostic value of serum C4d, PLA2R, THSD7A antibody in idiopathic membranous nephropathy and analysis of therapeutic effect of tacrolimus Diagnostic value of serum C4d, PLA2R, THSD7A antibody in idiopathic membranous nephropathy and analy ... | Diagnostic value of serum C4d, PLA2R, THSD7A antibody in idiopathic membranous nephropathy and analysis of therapeutic effect of tacrolimus Diagnostic value of serum C4d, PLA2R, THSD7A antibody in idiopathic membranous nephropathy and analy ... | Membranous nephropathy | 1:Prednisone + cyclophosphamide;2:Prednisone + Tacrolimus; | The First Affiliated Hospital of Bengbu Medical College | NULL | Pending | 17 | 70 | Both | 1:30;2:30; | Phase 4 | China |
4 | ChiCTR1800019833 | 2019-01-01 | 2018-12-02 | Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophosphamide combined with hormone Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophospha ... | Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophosphamide combined with hormone Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophospha ... | Idiopathic Membranous Nephropathy | PLA2R???:Cyclophosphamide combined with hormone therapy ;PLA2R positive Group:Cyclophosphamide combined with hormone therapy; PLA2R???:Cyclophosphamidecombined with hormone therapy ;PLA2R positive Group:Cyclophosphamidecombine ... | Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University | NULL | Pending | 18 | 85 | Male | PLA2R???:30;PLA2R positive Group:30; | China | |
5 | ChiCTR1800016140 | 2018-07-01 | 2018-05-14 | Comparison of the efficacy and safety of tacrolimus and glucocorticoid combined with cyclophosphamide in the treatment of adult primary membranous nephropathy: a multicenter, controlled, open study Comparison of the efficacy and safety of tacrolimus and glucocorticoid combined with cyclophosphamid ... | A randomized controlled trial for the treatment of primary membranous nephropathy | primary membranous nephropathy | Tacrolimus group:Tacrolimus 0.05-0.1mg/kg/d;Cyclophosphamide group:CTX 750mg/m2 ivgtt q2w for 8 weeks, then q4w for 4 weeks; Tacrolimusgroup:Tacrolimus0.05-0.1mg/kg/d;Cyclophosphamidegroup:CTX 750mg/m2 ivgtt q2w for 8 weeks, ... | Sichuan Provincial People's Hospital | NULL | Pending | 18 | 65 | Both | Tacrolimus group:45;Cyclophosphamide group:45; | China | |
6 | NCT03466801 (ClinicalTrials.gov) | March 20, 2018 | 13/1/2018 | The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I. The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamideon IM ... | The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I. The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamid ... | Idiopathic Membranous Nephropathy | Drug: Prednisone;Drug: MP and CTX | Wenhu Liu | NULL | Terminated | 18 Years | 80 Years | All | 6 | N/A | China |
7 | ChiCTR-IPR-17011702 | 2017-07-01 | 2017-06-19 | Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamide and steroid Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamidean ... | Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamide and steroid Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamidean ... | membranous nephropathy | mizoribine group:treated with mizoribine and steroid;cyclophosphamide group:treated with cyclophosphamide and steroid; mizoribinegroup:treated with mizoribineand steroid;cyclophosphamidegroup:treated with cyclophosphami ... | Tianjin First Central Hospital | NULL | Pending | 18 | 65 | Both | mizoribine group:50;cyclophosphamide group:50; | China | |
8 | ChiCTR-IPR-16008527 | 2016-06-01 | 2016-05-24 | Rituximab in the treatment of refractory membranous nephropathy: a multicenter, randomized, controlled clinical study Rituximab in the treatment of refractory membranous nephropathy: a multicenter, randomized, controll ... | Rituximab in the treatment of resistant membranous nephropathy: a multicenter, randomized, controlled clinical study Rituximab in the treatment of resistant membranous nephropathy: a multicenter, randomized, controlle ... | Membranous nephropathy | CsA group:oral CsA and glucosteroid;RTX group:intravenous RTX;CTX:Intravenous cyclophosphamide and glucosteroid; CsAgroup:oral CsAand glucosteroid;RTXgroup:intravenous RTX;CTX:Intravenous cyclophosphamideand gluco ... | Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine | NULL | Completed | 18 | 70 | Both | CsA group:60;RTX group:60;CTX:60; | Phase 4 | China |
9 | ChiCTR-IPR-16008344 | 2016-04-19 | 2016-04-22 | A study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid plus tacrolimus in idiopathic membranous nephropathy A study for comparing alternating glucocorticoid and cyclophosphamideversus glucocorticoid plus tacr ... | A study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid Plus tacrolimus in idiopathic membranous nephropathy A study for comparing alternating glucocorticoid and cyclophosphamideversus glucocorticoid Plus tacr ... | idiopathic membranous nephropathy | A:cyclophosphamide ;B:tacrolimus; | Baoji Central Hospital | NULL | Recruiting | Both | A:30;B:30; | China | |||
10 | EUCTR2013-000226-55-NL (EUCTR) | 04/03/2015 | 24/06/2014 | SEQUENTIAL THERAPY WITH TACROLIMUS AND RITUXIMAB IN PRIMARY MEMBRANOUS NEPHROPATHY | European Multicenter and Open-Label Controlled Randomized Trial to evaluate the Efficacy of Sequential Treatment with Tacrolimus-Rituximab versus Steroids plus Cyclophosphamide in patientes with Primary Membranous Nephropathy - STARMEN European Multicenter and Open-Label Controlled Randomized Trial to evaluate the Efficacy of Sequenti ... | Primary membranous nephropathy MedDRA version: 17.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] Primary membranous nephropathy MedDRA version: 17.0;Level: LLT;Classification code 10027170;Term: Me ... | Trade Name: Tacrolimus Product Name: TACROLIMUS INN or Proposed INN: TACROLIMUS Other descriptive name: TACROLIMUS Trade Name: MabThera Product Name: Rituximab INN or Proposed INN: RITUXIMAB Trade Name: Methylprednisolone Product Name: Methylprednisolone INN or Proposed INN: methylprednisolone Other descriptive name: METHYLPREDNISOLONE Trade Name: Prednisolone Product Name: Prednisolone INN or Proposed INN: prednisolone Other descriptive name: PREDNISOLONE ACETATE Trade Name: cyclophosphamide Product Name: cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Trade Name: Tacrolimus Product Name: TACROLIMUS INN or Proposed INN: TACROLIMUS Other descriptive name: ... | Fundacion Renal Iñigo Alvarez Toledo | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 175 | Spain;Netherlands |